BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 12596358)

  • 1. Recent advances in the pharmacogenetics of cancer chemotherapy.
    Watters JW; McLeod HL
    Curr Opin Mol Ther; 2002 Dec; 4(6):565-71. PubMed ID: 12596358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using genetic variation to optimize cancer chemotherapy.
    McLeod HL; Papageorgio C; Watters JW
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):107-11. PubMed ID: 16224389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics of cancer chemotherapy-induced toxicity.
    Miller CR; McLeod HL
    J Support Oncol; 2007 Jan; 5(1):9-14. PubMed ID: 17265780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development.
    Lee W; Lockhart AC; Kim RB; Rothenberg ML
    Oncologist; 2005 Feb; 10(2):104-11. PubMed ID: 15709212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics for individualized cancer chemotherapy.
    Efferth T; Volm M
    Pharmacol Ther; 2005 Aug; 107(2):155-76. PubMed ID: 15890408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacogenetics of anticancer drugs].
    de Chaisemartin L; Loriot MA
    Pathol Biol (Paris); 2005 Mar; 53(2):116-24. PubMed ID: 15708657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulfation through the looking glass--recent advances in sulfotransferase research for the curious.
    Coughtrie MW
    Pharmacogenomics J; 2002; 2(5):297-308. PubMed ID: 12439736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer pharmacogenomics: international trends.
    Yamayoshi Y; Iida E; Tanigawara Y
    Int J Clin Oncol; 2005 Feb; 10(1):5-13. PubMed ID: 15729594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics in cancer treatment.
    Nagasubramanian R; Innocenti F; Ratain MJ
    Annu Rev Med; 2003; 54():437-52. PubMed ID: 12525681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Value and applications of pharmacogenetics in oncology and hematology].
    Albin N; Massade L; Gouyette A
    Bull Cancer; 1997 Jun; 84(6):643-51. PubMed ID: 9295869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacogenomics: the quest for individualized therapy].
    López-López M; Guerrero-Camacho JL; Familiar-López IM; Jung-Cook H; Corona-Vázquez T; Alonso-Vilatela ME
    Rev Neurol; 2004 Dec 1-15; 39(11):1063-71. PubMed ID: 15597270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomics: bench to bedside.
    Weinshilboum R; Wang L
    Nat Rev Drug Discov; 2004 Sep; 3(9):739-48. PubMed ID: 15340384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacogenomic approaches for prevention of drug toxicity in cancer chemotherapy].
    Hasegawa Y
    Gan To Kagaku Ryoho; 2003 Mar; 30(3):325-33. PubMed ID: 12669388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy.
    Huang Y
    Cancer Metastasis Rev; 2007 Mar; 26(1):183-201. PubMed ID: 17323126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomic discovery approaches: will the real genes please stand up?
    Walgren RA; Meucci MA; McLeod HL
    J Clin Oncol; 2005 Oct; 23(29):7342-9. PubMed ID: 16145062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacogenetics and pharmacogenomics of cancers].
    Robert J
    Pathol Biol (Paris); 2004 Jul; 52(6):332-7. PubMed ID: 15261376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of pharmacogenetics in chemotherapy: modulation of tumour response and host toxicity.
    Boddy AV; Idle JR
    Cancer Surv; 1993; 17():79-104. PubMed ID: 8137354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug evaluation, drug development and pharmacogenetics: celebrating 30 years of progress.
    Li Wan Po A
    J Clin Pharm Ther; 2005 Feb; 30(1):1-4. PubMed ID: 15658998
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacogenomics in colorectal carcinomas: future perspectives in personalized therapy.
    Russo A; Corsale S; Cammareri P; Agnese V; Cascio S; Di Fede G; Macaluso M; Bazan V
    J Cell Physiol; 2005 Sep; 204(3):742-9. PubMed ID: 15828025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The importance of pharmacokinetic limited sampling models for childhood cancer drug development.
    Panetta JC; Iacono LC; Adamson PC; Stewart CF
    Clin Cancer Res; 2003 Nov; 9(14):5068-77. PubMed ID: 14613983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.